| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.007 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.007 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.007 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.007 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.008 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.19 | 0.01 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.01 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |